MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way-Reference-Cited by-同舟云学术

MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way

Published:2023-07-17 Issue:6 Volume:17 Page:1500-1518
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Fang Shiji,Zheng Liyun,Chen Xiaoxiao,Guo Xiaoju,Ding Yiming,Ma Ji,Ding Jiayi,Chen Weiqian,Yang Yang,Chen Minjiang,Zhao Zhongwei,Tu Jianfei,Ji Jiansong

Funder

Natural Science Foundation of Zhejiang Province

International Science and Technology Cooperation Programme

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-023-10565-2.pdf

Reference38 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249

2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390

3. Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87

4. Haber PK, Puigvehi M, Castet F, Lourdusamy V, Montal R, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). Gastroenterology. 2021;161:879–898

5. Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51: 102610

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of sorafenib resistance in hepatocellular carcinoma;Clinics and Research in Hepatology and Gastroenterology;2024-10

2. Advances in hepatocellular carcinoma drug resistance models;Frontiers in Medicine;2024-07-31

3. Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review);International Journal of Oncology;2024-07-31

4. Construction of a TP53 mutation-associated ceRNA network as prognostic biomarkers in hepatocellular carcinoma;Heliyon;2024-05

5. MEX3A Drives Triple-Negative Breast Cancer Migration, Invasion, and Metastasis by Interacting with NTRK1;J BIOL REG HOMEOS AG;2024